Background A subnormal cortisol response (30 min level (C 30min )<550 nmol/L) to synthetic adrenocorticotrophic hormone/Synacthen test (SDST) in all infants does not necessarily indicate underlying or persistent hypothalamic-pituitary-adrenal axis pathology. Methods We retrospectively evaluated the diagnoses and outcomes in 68 infants who had a SDST at age <6 months from 2011 to 2014. Results 29 (43%) infants had a subnormal SDST. Causative pathology was identified in 9/29 (31%). In 20/29 (69%) with no identified pathology, repeat SDST was normal in 18/20 (90%) at median age 0.6 (range 0.1-3.2) years but persistently subnormal in 2. Those with a transient abnormality were more likely to be small for gestational age (P=0.03) and had higher initial SDST C 30min (390 nmol/L vs 181 nmol/L, P=0.01) than those with pathology. Conclusion Specific aetiology can be identified in a third of infants with a subnormal SDST. When the aetiology remains elusive, adrenal function should be reassessed as the problem can be transient.
INTRODUCTION
Glucocorticoid deficiency (GD) can be life threatening due to hypoglycaemia, electrolyte disturbances and compromised cardiovascular homeostasis. To circumvent these potentially serious complications, timely diagnosis and adequate glucocorticoid replacement are essential. When GD is clinically suspected in infants, the gold standard to assess adrenal reserve is the standard dose Synacthen test (SDST) with synthetic adrenocorticotrophic hormone (ACTH). 1 Although a subnormal SDST supports the diagnosis of GD and further investigations are then required to identify causative aetiology, it does not necessarily imply underlying or persistent hypothalamic-pituitary-adrenal (HPA) axis pathology. A number of factors, such as immaturity of the HPA axis, can impact on the result of the SDST in early life 1 and be associated with transient abnormalities. In our tertiary endocrine practice, we have encountered infants with a subnormal SDST but no identifiable aetiology and normal adrenal reserve on reassessment. To gain greater insight into this problem, we evaluated the diagnoses and outcomes of infants who had a SDST in the first 6 months of life from a single tertiary regional centre.
METHODS
We retrospectively reviewed all infants who had a SDST within the first 6 months of life as part of their medical management between January 2011 and December 2014. All were managed at a single tertiary paediatric hospital. GD was clinically suspected due to combinations of the following features: hypoglycaemia, hyponatraemia, hypotension, unusual appearances of external genitalia and prolonged jaundice. Venous blood samples were taken before and 30 min after intravenous Synacthen 36 μg/kg. Plasma cortisol was measured using the Roche GEN I assay on the Cobas e602 analyser. The lower limit of quantification was <30 nmol/L and the intermediate precision coefficient of variations were less than 3%. For this assay, a 30 min cortisol (C 30min ) level <550 nmol/L with the SDST was defined as subnormal. 2 All infants with a subnormal SDST were clinically assessed by a consultant paediatric endocrinologist and investigated further (tests included ACTH levels, adrenal androgens and antibodies, very-long-chain fatty acids and pituitary imaging) to identify underlying HPA pathology, such as congenital adrenal hyperplasia and hypopituitarism. The SDST was repeated at 4 to 6 monthly intervals when no cause was identified.
Clinical 
What this study adds?
► This retrospective review of our clinical experience demonstrates that about twothirds of infants with subnormal SDST have no pathological cause identified despite thorough endocrine investigations. ► In such cases, adrenal function should be reassessed within 3 to 6 months and at regular intervals as GD may be transient.
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records. Transient GD was defined as those Infants who had a normal result (C 30min ≥550 nmol/L) on a repeat SDST and no identifiable cause for GD. Infants with birth length and/or weight at least two standard deviations (≤−2SD) below the mean for gestational age were classified as 'small for gestational age' (SGA). Statistical significance was determined using the χ 2 and Mann-Whitney U tests.
RESULTS
During this 4-year period, 68 infants (43 boys) underwent SDST for suspected GD at median age 7 weeks (range 0.1-27.1 weeks). Their median gestational age was 38 weeks: 40 born at term (≥37 weeks) and 28 preterm. Their diagnoses and outcomes are summarised in figure 1. The 39 (57%) infants (24 boys) who had a normal SDST result required no endocrine follow-up.
Underlying pathology for glucocorticoid deficiency
The 29/68 infants (43%; 19 boys) who had a subnormal SDST were grouped based on the presence (9 infants) or absence (20 infants) of underlying pathology ( figure 1, table 1 ). Three patients (one congenital hypopituitarism and two GD secondary to glucocorticoid treatment) died in hospital from complex medical problems, but none were due to an adrenal crisis.
The 20/29 (69%; 14 boys) infants in whom no pathology was identified were subgrouped based on the results of repeat SDST (figure 1). The transiently subnormal SDST subgroup comprised 18 infants in whom the repeat SDST result was normal (median C 30min 674 nmol/L, range 550-988 nmol/L) by median age 0.6 (range 0.1-3.2) years and within the first year in 10/18. These 18 infants were investigated for possible GD owing to recurrent hypoglycaemia (n=8), under-virilised genitalia/hypospadias (n=4), low cortisol levels when investigated for poor feeding and weight gain (n=2), prolonged neonatal jaundice (n=2), suspected hypopituitarism as part of septo-optic dysplasia (n=1) and persistent hyponatraemia (n=1).
Two of the 20 infants with no pathology identified were aged 5.2 and 2.9 years at last SDST and follow-up (ACTH levels 9 ng/L and <5 ng/L, respectively), have persistent isolated GD and remain on hydrocortisone replacement. The initial SDST was performed for suspected secondary adrenal insufficiency when they were investigated for prolonged neonatal jaundice, Figure 1 Outcomes and diagnoses of 68 infants who had a standard dose Synacthen test (SDST) for suspected glucocorticoid deficiency (GD). One infant with congenital hypopituitarism* (in addition to pulmonary hypertension and global developmental delay) and two with GD secondary to systemic glucocorticoid (GC) treatment** died (at ages 23 weeks, 26 weeks and 2.2 years, respectively) from other comorbidities. Two of the preterm infants who had transiently subnormal SDST were exposed to antenatal GC treatment***.
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as well as persistent hyponatraemia/hypoglycaemia and thyroid dysfunction in one infant and septic shock in the other.
Compared with those with identified GD aetiology, the transiently subnormal SDST subgroup were more likely to be SGA (P=0.03) and had higher C 30min on the initial SDST (P=0.01) (table 1). Their repeat SDST normalised at an earlier age in those born at term compared with preterm infants (median age 0.2 vs 1.6 years, P=0.03) (figure 1).
DISCUSSION
Our experience revealed that 43% infants clinically suspected to have GD had biochemical evidence of GD. However, only a third of these had causative HPA axis pathology and no cause was identified in the remainder despite comprehensive endocrine investigations. In addition, the majority of infants who had unexplained GD had a transiently subnormal SDST. These infants were more likely to be born SGA compared with infants with an identified cause for GD and adrenal function normalised considerably later in those born preterm compared with term (median 1.6 vs 0.2 years).
Transient GD in early life can be explained by a number of physiological processes including delayed postnatal remodelling of the HPA axis, immaturity of the adrenal enzymes involved in glucocorticoid synthesis, reduced adrenal gland perfusion, cytokine-induced suppression of ACTH/cortisol synthesis and tissue resistance to cortisol. [3] [4] [5] Under 30 weeks' gestation, cortisol synthesis by the fetal adrenal neocortex is limited by insufficient expression of 3β-hydroxysteroid dehydrogenase (HSD) and the fetus is thus dependent on maternal cortisol. Placental 11β-HSD2 metabolises maternal cortisol to inactive cortisone, but as its activity is attenuated in early gestation, more maternal cortisol crosses the placenta and suppresses the fetal HPA axis. 4 Rising levels of 11β-HSD2 during later gestation metabolises maternal cortisol to inactive cortisone, partially de-suppresses the fetal HPA axis and enables increasing fetal cortisol production. Placental corticotrophin-releasing hormone (CRH) also stimulates cortisol production by the fetal adrenal gland. 4 After birth and with the sudden withdrawal of these high concentrations of placental CRH, there is a lag in recovery of infant hypothalamic CRH secretion for several days. 4 5 When this brief refractory period is obtunded, pituitary corticotrophs are unable to optimally secrete ACTH and in turn stimulate adrenal glucocorticoid secretion, which appears to be well tolerated by healthy newborn infants. However, a prolonged state of transient GD when there is an inadequate response to acute stress may persist in ill infants and those born preterm or SGA. 4 Owing to the paucity of normative data for cortisol response to SDST in healthy infants, the cut-off of C 30min ≥550 nmol/L derived from studies of normal adults 2 was used to define GD in our cohort. We acknowledge the limitations of this, especially as basal cortisol secretion is lower in neonates compared with older individuals.
In conclusion, specific aetiology can be identified in a third of infants with a subnormal SDST. However, a subnormal test in the neonatal period does not necessarily imply serious or persistent underlying pathology. Using assay-specific cut-offs for the SDST C 30min in the neonatal period, a significant number of infants and especially those born preterm and SGA will have a transiently subnormal result up to age 4 years. We emphasise the importance of reassessing adrenal function within 3 to 6 months and at regular intervals thereafter when the aetiology remains elusive.
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